A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
Status:
Completed
Trial end date:
2018-11-19
Target enrollment:
Participant gender:
Summary
The purpose is to evaluate the efficacy and safety of three different doses of Dapirolizumab
Pegol (DZP) versus placebo in adult subjects with moderately to severely active systemic
Lupus Erythematosus.